“Cabotegravir”, the game changer injectable drug can combat HIV virus

A group of the researcher has recently found out a game-changing drug that can combat the virus of HIV. A medical experiment has recently been publicized for testing the effectiveness of a new injectable drug that can protect people from the infection of HIV virus. The individuals who have sex with men and transgender women and become infected with the virus of HIV can be safeguarded with a single shot of this injectable drug. Known as the ‘HPTN 083 study’, the medical trial aims to enhance the capability of the available preventive tools for the most vulnerable HIV virus.

The National Institutes of Health (NIH), last week declared about its entrance to the first-of-its-kind global medical trial of an injectable HIV-preventive remedy called cabotegravir. The clinical test will take place in eight major nations across three regions of the world including the Americas, Africa, and Asia. In this experiment, the scientists will be enrolled 4,500 gay and bisexual men alongside transgender women. All of the participants will be pulled from teams having the highest rates of new infections.

Spilling light on this matter, Raphael J. Landovitz, the Protocol Chair for the study, said, “The yearly number of new HIV contagions among juveniles, especially among young men having sex with men and transgender women previously have sexual relationship with men, has been noticed to take a hike in spite of the petite number of HIV incidence amongst adults across the world.”

The new clinical HIV Trail is titled as ‘HIV pre-exposure prophylaxes’ – an HIV defensive program and measure that includes the individuals who are extremely prone to HIV infection. In the new program, the researcher will take the sexually active gay men who have sexual intercourse with both gay men and transgender women having sex with other men. These types of men will be given an amalgamation of two oral HIV drugs on a daily basis.

Under the new clinical trial program, the researchers have involved around 4,500 patients having both men who have sex with men and transgender women. During the program, the participants are recruited from different leading countries like the US, Argentina, Brazil, Peru, India, Thailand, Vietnam, and South Africa. The study will go on up to 4.5 years.